Cynk-001

Neoplasms

Celularity IncorporatedCell therapyPhase 1Dormant

D

28/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 15/ 100
Competitive Position: 65/ 100

Competitive context

119 Active assets in the Neoplasms cohort.

Asset / Sponsor	Phase	Rating
DEXAMETHASONE Hellenic Society of Hematology	Phase 3	BB
Feladilimab GlaxoSmithKline	Phase 2	BB
Carboplatin Bristol-Myers Squibb	Phase 3	BB
Cetuximab Mirati Therapeutics Inc.	Phase 4	B
PREDNISONE TABLETS The First Affiliated Hospital of Soochow University	Phase 3	B

View all 50 →

Same molecule, other indications

Cynk-001 is also rated in:

giant cell glioblastomaDormant

C

Indicative ·

37 / 100

glioblastomaDormant

C

Indicative ·

37 / 100

monoclonal paraproteinemia diseaseDormant

D

Indicative ·

30 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.